{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumours&page=88",
    "query": {
      "condition": "Neuroendocrine Tumours",
      "page": 88
    },
    "page_size": 10
  },
  "pagination": {
    "page": 88,
    "page_size": 10,
    "total_count": 2742,
    "total_pages": 275,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumours&page=89&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumours&page=87&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T12:45:56.568Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02935790",
      "title": "Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "ACY-241",
          "type": "DRUG"
        },
        {
          "name": "nivolumab",
          "type": "DRUG"
        },
        {
          "name": "ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2016-09-30",
      "completion_date": "2017-04-07",
      "has_results": false,
      "last_update_posted_date": "2017-08-24",
      "last_synced_at": "2026-11-03T12:45:56.568Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02935790"
    },
    {
      "nct_id": "NCT07830225",
      "title": "A Pilot Study of ctDNA-Guided Immune Checkpoint Inhibitor Duration in Patients With Advanced Melanoma.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Melanoma (Skin Cancer)"
      ],
      "interventions": [
        {
          "name": "A Pilot Study of ctDNA-guided immune checkpoint inhibitor duration in patients with advanced melanoma",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 35,
      "start_date": "2026-09-03",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-11-03T12:45:56.568Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07830225"
    },
    {
      "nct_id": "NCT05004025",
      "title": "Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Uveal Melanoma"
      ],
      "interventions": [
        {
          "name": "Novocure Optune",
          "type": "DEVICE"
        },
        {
          "name": "Opdivo",
          "type": "DRUG"
        },
        {
          "name": "Yervoy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "HonorHealth Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 10,
      "start_date": "2022-02-28",
      "completion_date": "2025-07-23",
      "has_results": false,
      "last_update_posted_date": "2025-08-15",
      "last_synced_at": "2026-11-03T12:45:56.568Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05004025"
    },
    {
      "nct_id": "NCT02431676",
      "title": "Survivorship Promotion In Reducing IGF-1 Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Prostate Cancer",
        "Lung Cancer",
        "Colon Cancer",
        "Melanoma of Skin",
        "Endometrial Cancer",
        "Liver Cancer",
        "Pancreatic Cancer",
        "Rectal Cancer",
        "Kidney Cancer",
        "Other Solid Malignant Tumors"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Coach Directed Behavioral Weight Loss",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Self-control weight loss",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2015-05",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2024-08-28",
      "last_synced_at": "2026-11-03T12:45:56.568Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02431676"
    },
    {
      "nct_id": "NCT02038218",
      "title": "Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Brain Tumors",
        "Metastatic Malignant Neoplasm to Brain"
      ],
      "interventions": [
        {
          "name": "4-Demethyl-4-cholestryloxycarbonylpenclomedine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "DEKK-TEC, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2013-09",
      "completion_date": "2020-08",
      "has_results": true,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-11-03T12:45:56.568Z",
      "location_count": 3,
      "location_summary": "New Orleans, Louisiana • Lansing, Michigan • Houston, Texas",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02038218"
    },
    {
      "nct_id": "NCT05311618",
      "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Breast Cancer",
        "Gastric Cancer",
        "Non Small Cell Lung Cancer",
        "Cervical Cancer",
        "Endocervical Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Bladder Urothelial Cancer",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Ovarian Cancer",
        "Renal Cell Carcinoma",
        "Prostate Cancer",
        "Melanoma",
        "Mesothelioma",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "NGM438",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab (KEYTRUDA ®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NGM Biopharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2022-05-11",
      "completion_date": "2025-06",
      "has_results": false,
      "last_update_posted_date": "2024-04-01",
      "last_synced_at": "2026-11-03T12:45:56.568Z",
      "location_count": 6,
      "location_summary": "Denver, Colorado • New Haven, Connecticut • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05311618"
    },
    {
      "nct_id": "NCT04877613",
      "title": "GFRα4 CAR T Cells in MTC Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Medullary Thyroid Cancer",
        "Recurrent Thyroid Gland Medullary Carcinoma"
      ],
      "interventions": [
        {
          "name": "single dose of CART-GFRa4 cells",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2021-08-19",
      "completion_date": "2039-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-11-03T12:45:56.568Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04877613"
    },
    {
      "nct_id": "NCT05874817",
      "title": "Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17517,
      "start_date": "2021-05-01",
      "completion_date": "2022-05-20",
      "has_results": false,
      "last_update_posted_date": "2023-05-25",
      "last_synced_at": "2026-11-03T12:45:56.568Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05874817"
    },
    {
      "nct_id": "NCT00046189",
      "title": "Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Xeroderma Pigmentosum",
        "Basal Cell Carcinoma",
        "Squamous Cell Carcinoma",
        "Melanoma",
        "Skin Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "1 Month to 99 Years"
      },
      "enrollment_count": 301,
      "start_date": "2003-04-07",
      "completion_date": "2024-01-05",
      "has_results": false,
      "last_update_posted_date": "2024-01-08",
      "last_synced_at": "2026-11-03T12:45:56.568Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00046189"
    },
    {
      "nct_id": "NCT00002535",
      "title": "Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "lymphokine-activated killer cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic tumor infiltrating lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "indomethacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "St. Luke's Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1993-07",
      "completion_date": "2004-07",
      "has_results": false,
      "last_update_posted_date": "2013-06-26",
      "last_synced_at": "2026-11-03T12:45:56.568Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002535"
    }
  ]
}